Cyclopharm Limited provided sales guidance for the half year ended 30 June 2022. The company expected revenue is expected to be approximately $11.3 million, 36% higher than pcp and 74% higher than the company's pre-COVID revenues in first half 2019.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.68 AUD | +1.20% | +0.30% | -12.73% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.73% | 125M | |
+4.64% | 208B | |
+8.99% | 182B | |
+29.83% | 155B | |
+35.17% | 115B | |
+2.55% | 66.52B | |
+15.06% | 53.93B | |
-6.47% | 46.26B | |
-2.14% | 38.22B | |
+6.88% | 36.6B |
- Stock Market
- Equities
- CYC Stock
- News Cyclopharm Limited
- Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022